Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Short Interest Down 50.0% in February

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY - Get Free Report) was the target of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 800 shares, a drop of 50.0% from the February 13th total of 1,600 shares. Currently, 0.0% of the company's shares are short sold. Based on an average daily trading volume, of 559,900 shares, the short-interest ratio is currently 0.0 days.

Daiichi Sankyo Trading Up 3.5 %

Shares of DSNKY traded up $0.81 during midday trading on Tuesday, hitting $23.93. 358,479 shares of the stock were exchanged, compared to its average volume of 239,787. The firm has a market cap of $45.66 billion and a P/E ratio of 27.82. The stock has a fifty day simple moving average of $25.27 and a 200 day simple moving average of $29.82. Daiichi Sankyo has a 52-week low of $22.47 and a 52-week high of $42.48. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.11 and a current ratio of 2.77.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last released its earnings results on Friday, January 31st. The company reported $0.22 earnings per share (EPS) for the quarter. Daiichi Sankyo had a return on equity of 14.53% and a net margin of 13.62%. On average, research analysts anticipate that Daiichi Sankyo will post 0.73 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.